ECSP10010152A - Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa - Google Patents

Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa

Info

Publication number
ECSP10010152A
ECSP10010152A EC2010010152A ECSP10010152A ECSP10010152A EC SP10010152 A ECSP10010152 A EC SP10010152A EC 2010010152 A EC2010010152 A EC 2010010152A EC SP10010152 A ECSP10010152 A EC SP10010152A EC SP10010152 A ECSP10010152 A EC SP10010152A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
combination
oract
strategen
gestagen
Prior art date
Application number
EC2010010152A
Other languages
English (en)
Inventor
Beate Burglen
Manuela Pfeifer
Sabine Fricke
Claus Claussen
Ralf Ladwig
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP10010152A publication Critical patent/ECSP10010152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

. Los gestágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinación con estrógenos tales como, por ejemplo, etinilestradiol, 17ß-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepción oral sin lactosa. Se da una posibilidad para mejorar la prevención de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La invención también es apropiada para un uso prolongado.
EC2010010152A 2007-11-05 2010-05-05 Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa ECSP10010152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Publications (1)

Publication Number Publication Date
ECSP10010152A true ECSP10010152A (es) 2010-06-29

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010152A ECSP10010152A (es) 2007-11-05 2010-05-05 Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa

Country Status (30)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
ES2482104T3 (es) 2003-09-29 2014-08-01 Novo Nordisk Femcare Ag Formulaciones HRT
ES2933479T3 (es) 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
DK2217243T3 (da) 2014-10-20
HK1145289A1 (en) 2011-04-15
PL2217243T3 (pl) 2014-12-31
PA8803001A1 (es) 2009-06-23
AR069195A1 (es) 2010-01-06
CN101848716A (zh) 2010-09-29
UY31454A1 (es) 2009-05-29
CN101848716B (zh) 2012-11-28
ES2511841T3 (es) 2014-10-23
EP2217243A1 (de) 2010-08-18
DE202007019049U1 (de) 2010-05-12
EP2217243B1 (de) 2014-08-06
EP2774614A1 (de) 2014-09-10
BRPI0819189A2 (pt) 2015-05-26
TW200936142A (en) 2009-09-01
AT12800U1 (de) 2012-11-15
EA201000749A1 (ru) 2010-12-30
WO2009059690A1 (de) 2009-05-14
JP2011502136A (ja) 2011-01-20
SG188118A1 (en) 2013-03-28
IL205349A0 (en) 2010-12-30
EP2055306A1 (de) 2009-05-06
MX2010004975A (es) 2010-05-24
CO6270329A2 (es) 2011-04-20
DOP2010000130A (es) 2010-07-31
HRP20140962T1 (hr) 2014-12-05
KR20100103794A (ko) 2010-09-28
CR11413A (es) 2010-06-17
ZA201004024B (en) 2012-11-28
PT2217243E (pt) 2014-09-24
AU2008324549A1 (en) 2009-05-14
NZ585065A (en) 2012-06-29
DE202007019049U8 (de) 2010-09-30
PE20091020A1 (es) 2009-08-15
CA2704523A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
IN2012DN04867A (es)
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
MX2022012917A (es) Composiciones anticonceptivas con efectos adversos reducidos.
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
JP2008515909A5 (es)
CO6270329A2 (es) Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
MX2009000950A (es) Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
DE602004018921D1 (de) D dienogest
DE502006000771D1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva
GEP20135792B (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and use of the same
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
TH124135A (es)